Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice

BACKGROUND: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (NASH) are serious conditions and are being diagnosed at an increased rate. The etiology of these hepatic disorders is not clear but involves insulin resistance and oxidative stress. Remogliflozin etabonate (Remo) is an in...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Exp Hepatol
Main Authors: Nakano, Shigeru, Katsuno, Kenji, Isaji, Masayuki, Nagasawa, Tatsuya, Buehrer, Benjamin, Walker, Susan, Wilkison, William O., Cheatham, Bentley
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2015
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4632078/
https://ncbi.nlm.nih.gov/pubmed/26628836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jceh.2015.02.005
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares